Search alternatives:
ns decrease » _ decrease (Expand Search), we decrease (Expand Search), use decreased (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
ns decrease » _ decrease (Expand Search), we decrease (Expand Search), use decreased (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
4301
(A) The proportion of fast MyHC myotubes is decreased in Igf-2 deficient mice (maternal disomy Chromosome 7 - MatDi) at E14
Published 2011“…<p><b>Copyright information:</b></p><p>Taken from "A role for Insulin-like growth factor 2 in specification of the fast skeletal muscle fibre"</p><p>http://www.biomedcentral.com/1471-213X/7/65</p><p>BMC Developmental Biology 2007;7():65-65.…”
-
4302
-
4303
Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease
Published 2022“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
-
4304
Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease
Published 2022“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
-
4305
Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease
Published 2022“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
-
4306
Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease
Published 2022“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
-
4307
Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease
Published 2022“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
-
4308
Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease
Published 2022“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
-
4309
-
4310
Nitric Oxide Oxidatively Nitrosylates Ni(I) and Cu(I) <i>C</i>-Organonitroso Adducts
Published 2009“…[Me<sub>2</sub>NN]Cu(NCMe) reacts with 0.5 equiv of ArNO in ether to give the dinuclear adducts {[Me<sub>2</sub>NN]Cu}<sub>2</sub>(μ-η<sup>2</sup>:η<sup>1</sup>-ONAr) (<b>2a</b> and <b>2b</b>), which exhibit η<sup>2</sup> and η<sup>1</sup> bonding of the ArNO moiety with separate [Me<sub>2</sub>NN]Cu fragments possessing N−O distances of 1.375(6) Å (<b>2a</b>) and 1.368(2) Å (<b>2b</b>). …”
-
4311
Nitric Oxide Oxidatively Nitrosylates Ni(I) and Cu(I) <i>C</i>-Organonitroso Adducts
Published 2009“…[Me<sub>2</sub>NN]Cu(NCMe) reacts with 0.5 equiv of ArNO in ether to give the dinuclear adducts {[Me<sub>2</sub>NN]Cu}<sub>2</sub>(μ-η<sup>2</sup>:η<sup>1</sup>-ONAr) (<b>2a</b> and <b>2b</b>), which exhibit η<sup>2</sup> and η<sup>1</sup> bonding of the ArNO moiety with separate [Me<sub>2</sub>NN]Cu fragments possessing N−O distances of 1.375(6) Å (<b>2a</b>) and 1.368(2) Å (<b>2b</b>). …”
-
4312
Nitric Oxide Oxidatively Nitrosylates Ni(I) and Cu(I) <i>C</i>-Organonitroso Adducts
Published 2009“…[Me<sub>2</sub>NN]Cu(NCMe) reacts with 0.5 equiv of ArNO in ether to give the dinuclear adducts {[Me<sub>2</sub>NN]Cu}<sub>2</sub>(μ-η<sup>2</sup>:η<sup>1</sup>-ONAr) (<b>2a</b> and <b>2b</b>), which exhibit η<sup>2</sup> and η<sup>1</sup> bonding of the ArNO moiety with separate [Me<sub>2</sub>NN]Cu fragments possessing N−O distances of 1.375(6) Å (<b>2a</b>) and 1.368(2) Å (<b>2b</b>). …”
-
4313
Nitric Oxide Oxidatively Nitrosylates Ni(I) and Cu(I) <i>C</i>-Organonitroso Adducts
Published 2009“…[Me<sub>2</sub>NN]Cu(NCMe) reacts with 0.5 equiv of ArNO in ether to give the dinuclear adducts {[Me<sub>2</sub>NN]Cu}<sub>2</sub>(μ-η<sup>2</sup>:η<sup>1</sup>-ONAr) (<b>2a</b> and <b>2b</b>), which exhibit η<sup>2</sup> and η<sup>1</sup> bonding of the ArNO moiety with separate [Me<sub>2</sub>NN]Cu fragments possessing N−O distances of 1.375(6) Å (<b>2a</b>) and 1.368(2) Å (<b>2b</b>). …”
-
4314
Nitric Oxide Oxidatively Nitrosylates Ni(I) and Cu(I) <i>C</i>-Organonitroso Adducts
Published 2009“…[Me<sub>2</sub>NN]Cu(NCMe) reacts with 0.5 equiv of ArNO in ether to give the dinuclear adducts {[Me<sub>2</sub>NN]Cu}<sub>2</sub>(μ-η<sup>2</sup>:η<sup>1</sup>-ONAr) (<b>2a</b> and <b>2b</b>), which exhibit η<sup>2</sup> and η<sup>1</sup> bonding of the ArNO moiety with separate [Me<sub>2</sub>NN]Cu fragments possessing N−O distances of 1.375(6) Å (<b>2a</b>) and 1.368(2) Å (<b>2b</b>). …”
-
4315
Nitric Oxide Oxidatively Nitrosylates Ni(I) and Cu(I) <i>C</i>-Organonitroso Adducts
Published 2009“…[Me<sub>2</sub>NN]Cu(NCMe) reacts with 0.5 equiv of ArNO in ether to give the dinuclear adducts {[Me<sub>2</sub>NN]Cu}<sub>2</sub>(μ-η<sup>2</sup>:η<sup>1</sup>-ONAr) (<b>2a</b> and <b>2b</b>), which exhibit η<sup>2</sup> and η<sup>1</sup> bonding of the ArNO moiety with separate [Me<sub>2</sub>NN]Cu fragments possessing N−O distances of 1.375(6) Å (<b>2a</b>) and 1.368(2) Å (<b>2b</b>). …”
-
4316
-
4317
-
4318
-
4319
-
4320